Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.

A Randomized Post-Marketing Efficacy And Safety Study Of Xalatan Compared With Usual Care Over 36 Months In Patients With Primary Open-Angle Glaucoma, Exfoliative Glaucoma Or Ocular Hypertension

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00140062

Enrollment

329

Registered

2005-08-31

Start date

2002-02-28

Completion date

2006-04-30

Last updated

2008-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Open-Angle, Ocular Hypertension

Brief summary

The primary purpose is to compare the intraocular pressure reducing effect of Xalatan with that of usual care over 36 months. Safety and health care utilization will be evaluated.

Interventions

DRUGlatanoprost 0.005% (Xalatan)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Unilateral or bilateral open-angle glaucoma, exfoliative glaucoma, pigmentary glaucoma or ocular hypertension * IOP of \> 21 mm Hg on current treatment

Exclusion criteria

* Any previous or current treatment with latanoprost or other prostaglandin analogues

Design outcomes

Primary

Measure	Time frame
Time to treatment failure (change or addition of ocular hypertensive medical treatment, ocular surgery or laser trabeculoplasty) of latanoprost monotherapy or usual care over 36 months.	—

Secondary

Measure	Time frame
Safety and the health care utilization in the two treatment groups over 36 months.	—

Countries

Finland, Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026